Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.15+0.54 (+2.19%)
At close: 04:00PM EDT
25.18 +0.03 (+0.12%)
After hours: 07:10PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close24.61
Open24.35
Bid23.54 x 800
Ask25.10 x 900
Day's Range23.77 - 25.54
52 Week Range13.59 - 26.13
Volume1,215,957
Avg. Volume565,750
Market Cap1.482B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.67
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARQT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arcutis Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/02/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update

    Received U.S. Food and Drug Administration (FDA) approval for ZORYVE™ (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis, in individuals 12 years of age and olderAnnounced positive topline results from pivotal Phase 3 trial of roflumilast foam in seborrheic dermatitis, with anticipated New Drug Application (NDA) submission in the first quarter of 2023Completed enrollment in INTEGUMENT-1, the first of two pivotal Phase 3 trials in subjects with atop

  • Investor's Business Daily

    Arcutis Biothera Stock Joins Rank Of Stocks With RS Ratings Over 90

    Arcutis Biothera shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

  • GlobeNewswire

    Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

    A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022Atopic dermatitis affects approximately 26 million adults and children in the U.S. WESTLAKE VILLAGE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatolog

Advertisement
Advertisement